000282603 001__ 282603
000282603 005__ 20251211161559.0
000282603 0247_ $$2doi$$a10.1177/13872877251389147
000282603 0247_ $$2pmid$$apmid:41252287
000282603 0247_ $$2ISSN$$a1387-2877
000282603 0247_ $$2ISSN$$a1875-8908
000282603 037__ $$aDZNE-2025-01361
000282603 041__ $$aEnglish
000282603 082__ $$a610
000282603 1001_ $$0P:(DE-2719)2811856$$aLohner, Valerie$$b0
000282603 245__ $$aProspective associations of blood-based biomarkers of neurodegenerative diseases with cognitive performance in a cohort of patients with chronic coronary syndrome.
000282603 260__ $$aAmsterdam$$bIOS Press$$c2025
000282603 3367_ $$2DRIVER$$aarticle
000282603 3367_ $$2DataCite$$aOutput Types/Journal article
000282603 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1765466052_17917
000282603 3367_ $$2BibTeX$$aARTICLE
000282603 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282603 3367_ $$00$$2EndNote$$aJournal Article
000282603 520__ $$aIn a cohort of persons with chronic coronary syndrome, we investigated associations of blood-based biomarkers of neurodegenerative diseases with cognitive scores and mild cognitive impairment (MCI) after ten years. Biomarker levels were measured in baseline samples of serum (glial fibrillary acid protein, neurofilament light chain (NfL), phosphorylated tau181; n = 363) or plasma (amyloid-β42/40-ratio, total-tau; n = 232). Cognitive scores and MCI were measured at ten-year follow-up using the Cognitive Telephone Screening Instrument. At follow-up, 14.7% had MCI. The amyloid-β42/40-ratio was predictive of cognitive scores, while NfL was associated with increased risk of MCI, suggesting that these biomarkers might be utilized for risk stratification.
000282603 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000282603 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000282603 650_7 $$2Other$$aAlzheimer's disease
000282603 650_7 $$2Other$$aamyloid-beta ratio
000282603 650_7 $$2Other$$abiomarkers of neurodegenerative diseases
000282603 650_7 $$2Other$$achronic coronary syndrome
000282603 650_7 $$2Other$$acognition
000282603 650_7 $$2Other$$aepidemiology
000282603 650_7 $$2Other$$amild cognitive impairment
000282603 650_7 $$2Other$$aneurofilament light chain
000282603 650_7 $$2NLM Chemicals$$aBiomarkers
000282603 650_7 $$2NLM Chemicals$$aNeurofilament Proteins
000282603 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000282603 650_7 $$2NLM Chemicals$$atau Proteins
000282603 650_7 $$2NLM Chemicals$$aPeptide Fragments
000282603 650_7 $$2NLM Chemicals$$aneurofilament protein L
000282603 650_7 $$2NLM Chemicals$$aGlial Fibrillary Acidic Protein
000282603 650_2 $$2MeSH$$aHumans
000282603 650_2 $$2MeSH$$aMale
000282603 650_2 $$2MeSH$$aFemale
000282603 650_2 $$2MeSH$$aBiomarkers: blood
000282603 650_2 $$2MeSH$$aAged
000282603 650_2 $$2MeSH$$aCognitive Dysfunction: blood
000282603 650_2 $$2MeSH$$aCognitive Dysfunction: psychology
000282603 650_2 $$2MeSH$$aNeurofilament Proteins: blood
000282603 650_2 $$2MeSH$$aMiddle Aged
000282603 650_2 $$2MeSH$$aAmyloid beta-Peptides: blood
000282603 650_2 $$2MeSH$$atau Proteins: blood
000282603 650_2 $$2MeSH$$aProspective Studies
000282603 650_2 $$2MeSH$$aNeurodegenerative Diseases: blood
000282603 650_2 $$2MeSH$$aNeurodegenerative Diseases: complications
000282603 650_2 $$2MeSH$$aCohort Studies
000282603 650_2 $$2MeSH$$aPeptide Fragments: blood
000282603 650_2 $$2MeSH$$aGlial Fibrillary Acidic Protein: blood
000282603 650_2 $$2MeSH$$aNeuropsychological Tests
000282603 650_2 $$2MeSH$$aCognition: physiology
000282603 7001_ $$aPerna, Laura$$b1
000282603 7001_ $$aSchöttker, Ben$$b2
000282603 7001_ $$0P:(DE-2719)2812234$$aPerneczky, Robert$$b3$$udzne
000282603 7001_ $$aKliegel, Matthias$$b4
000282603 7001_ $$aBrenner, Hermann$$b5
000282603 7001_ $$aMons, Ute$$b6
000282603 773__ $$0PERI:(DE-600)2070772-1$$a10.1177/13872877251389147$$gVol. 108, no. 4, p. 1507 - 1513$$n4$$p1507 - 1513$$tJournal of Alzheimer's disease$$v108$$x1387-2877$$y2025
000282603 8564_ $$uhttps://pub.dzne.de/record/282603/files/DZNE-2025-01361_Restricted.pdf
000282603 8564_ $$uhttps://pub.dzne.de/record/282603/files/DZNE-2025-01361_Restricted.pdf?subformat=pdfa$$xpdfa
000282603 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812234$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000282603 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000282603 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-20
000282603 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-20
000282603 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-20
000282603 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-20
000282603 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-20
000282603 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-20
000282603 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-20
000282603 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-20
000282603 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-20
000282603 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-20
000282603 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-20
000282603 9201_ $$0I:(DE-2719)5000022$$kAG Dichgans$$lVascular Cognitive Impairment & Post-Stroke Dementia$$x0
000282603 980__ $$ajournal
000282603 980__ $$aEDITORS
000282603 980__ $$aVDBINPRINT
000282603 980__ $$aI:(DE-2719)5000022
000282603 980__ $$aUNRESTRICTED